The ALDH1A1 Knockout HEK293T Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HEK293T human embryonic kidney cell line, in which the ALDH1A1 gene has been disrupted to eliminate its enzymatic function. This loss-of-function model enables the dissection of retinoic acid biosynthesis and aldehyde detoxification pathways, providing a powerful tool for investigating signaling mechanisms in cancer, development, and metabolism.
HEK293T cells are a fast-growing, highly transfectable variant of the 293 cell line that stably expresses the SV40 large T-antigen, allowing episomal replication of plasmids containing the SV40 origin of replication. This host cell line is widely employed for transient and stable protein expression, viral vector production, and functional genomic studies due to its robust growth characteristics and high transfection efficiency. The HEK293T background is particularly suited for experiments requiring efficient genetic manipulation and strong gene expression, making it an ideal platform for CRISPR/Cas9-mediated knockout studies.
ALDH1A1 encodes a cytosolic aldehyde dehydrogenase that catalyzes the NAD+-dependent oxidation of retinaldehyde to all-trans retinoic acid, a critical step in the retinoic acid biosynthesis pathway. The product retinoic acid acts as a ligand for nuclear retinoic acid receptors (RAR??, RAR??, RAR??) that heterodimerize with retinoid X receptors (RXR??, RXR??, RXR??) to regulate transcription of target genes involved in cell differentiation, proliferation, and stem cell maintenance, including HOX cluster genes and RAR?? itself. ALDH1A1 expression is transcriptionally regulated by upstream signals such as all-trans retinoic acid (ATRA) via RAR/RXR heterodimers, ??-catenin/TCF complexes, NF-??B, Notch, and STAT3, linking this enzyme to Wnt/??-catenin and inflammatory cytokine pathways. ALDH1A1 functions as a homotetramer, interacting with its substrate retinaldehyde produced by RDH10, and its activity is modulated by CRABP2 and the catabolic enzyme CYP26A1, forming a tightly regulated signaling network.
In the HEK293T cellular context, knockout of ALDH1A1 eliminates the capacity for de novo retinoic acid synthesis from retinaldehyde, thereby disrupting downstream RAR/RXR-mediated transcriptional programs. This genetic ablation provides a clean background to study retinoic acid-dependent signaling events without confounding endogenous enzyme activity, and the polyclonal nature of the knockout population minimizes clonal variation artifacts while preserving overall genetic heterogeneity. The model is therefore suited for investigating how loss of ALDH1A1 impacts stem cell-like phenotypes, detoxification of reactive aldehydes, and cross-talk among the signaling pathways that converge on retinoic acid homeostasis.
This polyclonal knockout cell product is applicable to a broad range of experimental workflows, including quantitative analysis of retinoic acid metabolites by LC-MS, assessment of aldehyde dehydrogenase activity using the Aldefluor flow cytometry assay, and molecular profiling of gene expression changes via RT-qPCR or Western blotting. Researchers can employ these cells to dissect the role of ALDH1A1 in cancer stem cell maintenance in malignancies such as breast, lung, colorectal, and head and neck squamous cell carcinoma, as well as in alcohol-related liver disease and drug metabolism studies. Additionally, these knockout cells facilitate developmental biology investigations of retinoic acid gradient formation and cellular differentiation assays. The genetic modification can be validated by Sanger sequencing or NGS; for further technical details or customized applications, please contact Ascent Research.
